Ethyl-3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1- methyl-1h-benzimidazol-5-carbonyl)-pyridine-2-yl-amino]-propionic acid ethyl ester methane sulphonate in crystalline form ii, pharmaceutical composition comprising it and uses thereof for preparing pharmaceutical compositions which are suitable for the post-operative prophylaxis of deep vein thrombosis and the prevention of stroke and process for the preparation thereof
Gegenstand der vorliegenden Erfindung ist die Verbindung 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester - Methansulfonat in den Kristallmodifikationen I und II sowie als Hemihydrat und deren Verwendung als Arzneimittel.The invention relates to the compound 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridine-2-yl-amino]-propionic acid-ethyl ester methane sulphonate in crystal modifications I and II and also as a hemihyrate in addition to the use thereof as a medicament.La présente invention concerne le composé éthylester-méthansulfonate dacide 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phénylamino]-méthyl}-1-méthyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionique dans les modifications cristallines I et II et en tant que semi-hydrate, ainsi que son utilisation en tant que médicament.
